COVID-19大流行对急性缺血性卒中治疗时间的影响:血管与介入神经病学会多中心协作研究
本研究汇总了14家美国综合性卒中中心2019年1月1日至2020年7月31日的连续成人卒中患者数据,比较疫情前(2019年3月1日至7月31日)与疫情期间(2020年3月1日至7月31日)溶栓治疗达标率及时间指标。结果显示,疫情期间患者到达后60分钟内接受溶栓的几率降低(OR 0.61, 95%CI 0.38-0.98; P=0.04), door-to-needle时间中位延迟4分钟(P=0.03),调整后仍显著(aOR 0.55, 95%CI 0.35-0.85; P<0.01);延迟主要源于影像到推注时间延长(中位29 vs 22分钟,P=0.02),而取栓时间无显著延迟。
要点
- 疫情期间急性缺血性卒中患者60分钟内溶栓的几率显著降低。
- 溶栓延迟主要来自影像到推注时间延长,取栓时间未受显著影响。
- 减少影像到推注时间的延迟或可减轻疫情的间接影响。
核心结论
- COVID-19期间急性缺血性卒中评估与静脉溶栓的小幅但显著延迟相关,而取栓时间指标无显著延迟。
研究设计与样本
- 多中心回顾性队列研究,汇总14家美国综合性卒中中心连续成人卒中患者数据。
- 共纳入2955例患者,疫情前组1491例,疫情期间组1464例。
主要发现
- 疫情期间患者到达后60分钟内接受溶栓的几率降低(OR 0.61, 95%CI 0.38-0.98; P=0.04)。
- door-to-needle时间中位延迟4分钟(P=0.03)。
- 调整所有与早期治疗相关变量后,达标几率仍降低(aOR 0.55, 95%CI 0.35-0.85; P<0.01)。
- 影像到推注时间中位延长(29 [IQR 18-41] vs 22 [IQR 13-37] 分钟; P=0.02)。
- 取栓患者door-to-groin puncture时间无显著延迟(83 [IQR 63-133] vs 90 [IQR 73-129] 分钟; P=0.30)。
关键数值与推荐
- Target: Stroke目标为到达后60分钟内接受溶栓治疗。
- 疫情期间静脉溶栓率在纳入患者中为15%。
临床怎么用
- 疫情期间应关注急性缺血性卒中溶栓流程,尤其缩短影像到推注时间。
- 取栓时间指标未受显著影响,可维持现有流程。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The pandemic caused by the novel coronavirus disease 2019 (COVID-19) has led to an unprecedented paradigm shift in medical care. We sought to evaluate whether the COVID-19 pandemic may have contributed to delays in acute stroke management at comprehensive stroke centers. METHODS: Pooled clinical data of consecutive adult stroke patients from 14 US comprehensive stroke centers (January 1, 2019, to July 31, 2020) were queried. The rate of thrombolysis for nontransferred patients within the Target: Stroke goal of 60 minutes was compared between patients admitted from March 1, 2019, and July 31, 2019 (pre-COVID-19), and March 1, 2020, to July 31, 2020 (COVID-19). The time from arrival to imaging and treatment with thrombolysis or thrombectomy, as continuous variables, were also assessed. RESULTS: Of the 2955 patients who met inclusion criteria, 1491 were admitted during the pre-COVID-19 period and 1464 were admitted during COVID-19, 15% of whom underwent intravenous thrombolysis. Patients treated during COVID-19 were at lower odds of receiving thrombolysis within 60 minutes of arrival (odds ratio, 0.61 [95% CI, 0.38-0.98]; P=0.04), with a median delay in door-to-needle time of 4 minutes (P=0.03). The lower odds of achieving treatment in the Target: Stroke goal persisted after adjustment for all variables associated with earlier treatment (adjusted odds ratio, 0.55 [95% CI, 0.35-0.85]; P<0.01). The delay in thrombolysis appeared driven by the longer delay from imaging to bolus (median, 29 [interquartile range, 18-41] versus 22 [interquartile range, 13-37] minutes; P=0.02). There was no significant delay in door-to-groin puncture for patients who underwent thrombectomy (median, 83 [interquartile range, 63-133] versus 90 [interquartile range, 73-129] minutes; P=0.30). Delays in thrombolysis were observed in the months of June and July. CONCLUSIONS: Evaluation for acute ischemic stroke during the COVID-19 period was associated with a small but significant delay in intravenous thrombolysis but no significant delay in thrombectomy time metrics. Taking steps to reduce delays from imaging to bolus time has the potential to attenuate this collateral effect of the pandemic.
引用
- Siegler JE, Zha AM, Czap AL, et al. Influence of the COVID-19 Pandemic on Treatment Times for Acute Ischemic Stroke: The Society of Vascular and Interventional Neurology Multicenter Collaboration. Stroke. 2020. PMID: 33250041. doi:10.1161/STROKEAHA.120.032789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。